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Abstract 
Purpose: To build a microRNA and gene signature of severe cutaneous adverse drug reactions 
(SCAR), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). 
Methods: MicroRNA expression profiles were downloaded from miRNA expression profile of patients’ 
skin suffering from TEN using an array comprising of 372 miRNAs; download site: www.jacionline.org. 
The patient samples were eight TEN, ten SJS patients and twenty-two healthy individuals. A total of 192 
microRNAs were found with unique expression patterns (overexpressed) in contrast with healthy skin 
controls and patients. Thereafter, the following databases were used for downstream analysis: 
geneMANIA, DIANA-miRPath version 3, DIANA-TarBase version 7.0, Ingenuity Pathway Analysis (IPA) 
as well as DAVID, STRING and GENECODIS online tools. 
Results: Granulysin (GNLY) geneMANIA database search yielded 21 interacting genes that were 64.6 
% in physical interaction, 17 % in co-expression pattern.  miRBD potential microRNAs that target the 21 
genes were 79 miRs. Eighteen miRs overlap between the overexpressed miRs from SJS/TEN samples 
and the miRs targeting the 21 genes. Moreover, Ingenuity pathway analysis IPA revealed that the 
microRNAs were involved in inflammation.  
Conclusion: Analysis of differential microRNA expressions reveals two significant DE miRs that target 
Granulysin (483-5p/miR-28-5p). MiR-GNLY loop interactions in hypersensitivity reactions may function 
as biomarkers for SCAR including SJS and TEN.   
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The clinical appearances of Stevens-Johnson 
syndrome (SJS) and toxic epidermal necrolysis 
(TEN range from mild severe cutaneous adverse 
drug reactions (SCAR), both are rare but seldom 
fatal. Yet, morbidity and mortality is in rapid 
increase worldwide [1]. The pathogenesis of 
SCAR is a compound and multifactorial. It is 
known that drug antigen interactions, genetic 
background, and environmental factors might be 
involved [2]. SCAR are among the most 
significant serious skin conditions amid 
cutaneous drug-provoked hypersensitivity 
adverse conditions [3].  SJS and TEN rely on 
immune mediators in their hypersensitivity 
reactions that involve the cutaneous tissues and 
layers [4]. Mortality still occurs in over 5 % of 
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hypersensitivity adverse patients with SJS and 
greater than 30 % of the same patients [5]. 
Nevertheless, the mechanisms of SJS and TEN 
are not fully elucidated. MicroRNAs or miRs are 
single stranded RNAs that are capable of 
posttranscriptional gene regulation via targeting 
their Mrna [6]. MicroRNAs are very important 
regulators in many human diseases, for instance, 
cancer [7]. Here, microRNAs are imposed as 
new regulators in adverse cutaneous reactions 
[8]. T-cell lymphocyte association with SJS and 
TEN was recently observed to be linked with skin 
reactions, in addition to the recently reported 
Granulysin and natural killer cells inhibitory 
receptors [9]. Currently, Granulysin acts as the 
substantial player and responsible for the 
dispersed keratinocyte death [10] and it has a 
role in cytotoxic T lymphocyte conditions [11]. 
 
In addition to Granulysin, multiple reports have 
revealed that numerous cytokines contributing an 
essential role in the apoptosis (programmed cell 
death) and/or the cytokine inflammations. In 
other reports levels of SJS and TEN cytokines 
were considerably greater in patient serum than 
healthy individuals’ [12]. 
 
In the current study, Granulysin is deemed to 
establish core regulator and mediator along with 
his related/co-expressed genes and microRNAs 
for SJS and TEN pathogenesis. The databases 
and software used in this work not only attain 
information for DEG miRs in severe cutaneous 
SJS and TEN reactions, but also facilitate the 
approach towards discovering substantial roles in 




Database and topological investigations  
 
MicroRNAs array: differentially expressed in 
SCAR 
 
MicroRNA expression profile were downloaded 
from the inclusive miRNA expression profile of 
patients skin suffering from TEN using an array 
comprising of 372 miRNAs; Ichihara et al article's 
Online Repository at www.jacionline.org [13]. 
The samples were achieved from eight TEN 
patients, ten SJS patients with and 22 healthy 
volunteers. A total of 192 microRNAs were found 
with distinctive expressions patterns 
(overexpressed) in contrast between healthy skin 
controls and patients. Then we upload the 
overexpressed miRs to DIANA-miRPath v3. to 
obtain the significant gene list and pathways [14]. 
 
Granulsyin core gene 
 
We loaded Granulsyin gene (GNLY) to 
geneMANIA database [15]; this search was 
important to reveal the intern actions between 
this core gene in SJS and TEN with other genes 
and microRNAs. This search yielded 21 genes 
that most interacting with GNLY. 
 
MicroRNAs targeting Granulsyin gene 
 
Characterization of the GNLY expression profiles 
using, DIANA-TarBase v7.0 to find the potential 
microRNAs targeting these genes [16]. 
 
Functional annotation by DAVID web tool  
 
DAVID stands for: Database for Annotation, 
Visualization and Integrated Discovery. DAVID 
tool was used to annotate/confirm the function of 
the genes list related to Granulysin. Selection of 
Gene Ontology GO standings with adjusted p-
value less than 0.05. 
 
Network and Pathway analysis by Ingenuity 
Pathway Analysis IPA 
 
The twenty-one genes related to Granulysin were 
then investigated and characterized in KEGG 
(Kyoto Encyclopedia of Genes and Genomes) 
[17], Ingenuity Pathway Analysis (IPA) tools by 
the GENECODIS software [18]. REACTOME, is 
a tools for the visualization, interpretation and 
analysis of pathway knowledge to support basic 
research, genome analysis, modeling, systems 




1-DIANA-miRPath 70 pathway results for the 
microRNA 
 
This search yielded more than 70 significant 
pathways; we chose the top ten according to p 
Value result and number of genes targeted by 
the miR list loaded to DIANA-miRPath tool. All 
summarized in Table 1. 
 
2-GeneMANIA database results for 
Granulsyin gene   
 
Granulsyin gene (GNLY)/geneMANIA database 
[15], search yielded 21 genes that most 
interacting with GNLY. 
 
3-MicroRNAs is targeting Granulsyin gene in 
prediction database  
 
DIANA-TarBase v7.0 to confirm the microRNAs 
targeting these genes [16]. This search yielded 
around 20 miRs that target GNLY gene. Using 
the original database DEG miRs (192 miRs). 
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Two miRs were overexpressed in SJS and TEN 
were among the newly identified from DIANA-
TarBase Search. They are miR-483-5p/miR-28-
5p. This confirm the role of both microRNAs-and 
their target granulysin protein. 
 
MicroRNAs targeting 21 Granulsyin-related 
genes 
 
In order to further characterize the 21 Granulsyin 
co-expressed genes, all genes were applied to    
DIANA-TarBase to find the potential microRNA 
targeting them.  
 
The miRs found to be potential regulators are 
shown in Table 2. 
 
After loading the whole gene list of 21 gene 
names. More accurate list with more genes and 
microRNA were acquired from MirDB database 
(The target prediction database, miRDB) [20]. 
 
           Table 1: DIANA-miRPath pathway results for the microRNA list 
 
KEGG pathway P-value #Genes #miRNAs 
Proteoglycans in cancer 4.34E-12 164 88 
Mucin type O-Glycan biosynthesis 3.25E-11 26 51 
Morphine addiction 1.90E-09 76 83 
Pathways in cancer 7.86E-08 306 89 
Axon guidance 1.01E-07 107 85 
ErbB signaling pathway 3.16E-07 77 81 
ECM-receptor interaction 5.84E-07 64 77 
Rap1 signaling pathway 8.89E-07 171 87 




Figure 1: The twenty-one genes that interacted most with GNLY 
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Table 2: DIANA-TarBase for the 21 genes interacting with Granulysin gene/GNLY 
 
Gene miR Score Method 
NFKB1  
 
hsa-miR-9-5p   






IL2RB (hsa)    
  
hsa-miR-335-3p    
 
0.908 Immunoprecipitation (IP) 
SLA (hsa)    
 
hsa-miR-155-5p    0.907 Immunoprecipitation (IP) 
IL2RB  hsa-miR-424-5p    
hsa-miR-629-5p    
 hsa-miR-497-5p    
hsa-miR-34a-5p    
hsa-miR-449a    
hsa-miR-186-3p    
hsa-miR-449b-5p    
hsa-miR-195-5p    
 hsa-miR-16-5p    












SLA  hsa-miR-23b-3p    
 hsa-miR-23a-3p    








AOAH hsa-miR-199a-5p    




CTSW hsa-miR-335-5p    
hsa-miR-129-2-3p    







PSAP hsa-miR-454-3p       
hsa-miR-301a-3p    
hsa-miR-301b    
hsa-miR-130a-3p    
hsa-miR-130b-3p    
hsa-miR-3127-5p    
hsa-miR-19b-3p    
 hsa-miR-296-3p    
 hsa-miR-19a-3p    













JUN hsa-miR-200b-3p    






GZMK   
 
hsa-miR-335-5p   - - 
SFTPB     
 
hsa-miR-199a-5p   - - 
CCL5    hsa-miR-125a-5p   - - 
 
We scrutinized our search for microRNAs that 
are predicted to target the 21 genes and the 
overexpressed 193 miRs and found 18 miRs 
overlapping, summarized in Table 3. 
 
DAVID Functional annotation results  
 
The DAVID tool [21], yielded six important cluster 
enrichments score were as follows 5.26, 3.14, 
3.04, 2.85, 1.87 and 0.06.  
 
Most related to SJS/TEN are Chemokine 
signaling pathway, inflammatory response and 
Natural killer cell mediated cytotoxicity. 
 
Network/pathway analysis by ingenuity 
pathway analysis  
 
IPA for 21 genes related to Granulysin were then 
investigated and characterized in KEGG (Kyoto 
Encyclopedia of Genes and Genomes) [17], 
Ingenuity Pathway Analysis (IPA) tools by the 
GENECODIS software [18]. REACTOME, is a 
tools for the visualization, interpretation and 
analysis of pathway knowledge to support basic 
research, genome analysis, modeling, systems 
biology and education [19]. 
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IPA results for Granulysin and the important 21 genes are shown in Figure 2. 
Table 3: The 18 microRNAs validated by PCR to be overexpressed in SJS/TEN and targeting 
granulysin-related genes 
 
Ranking Target mark miRNA Tag Gene  Gene full name 
5 97 miR-301b-3p PSAP prosaposin 
7 96 miR-19b-3p PSAP prosaposin 
8 95 miR-92a-1-5p CXCL9  chemokine (C-X-C motif) ligand 9 
12 94 miR-200c-3p JUN jun proto-oncogene 
18 88 miR-661 KLRD1 killer cell lectin-like receptor subfamily D, member 1 
27 80 miR-34a-5p IL2RB interleukin 2 receptor, beta 
28 80 miR-449a IL2RB interleukin 2 receptor, beta 
29 80 miR-34c-5p IL2RB interleukin 2 receptor, beta 
43 74 miR-411-5p KLRD1 killer cell lectin-like receptor subfamily D, member 1 
55 66 miR-125b-5p PSAPL1 prosaposin-like 1 (gene/pseudogene) 
62 65 miR-342-5p PSAPL1 prosaposin-like 1 (gene/pseudogene) 
63 64 miR-145-3p GZMK granzyme K (granzyme 3; tryptase II) 
65 63 miR-454-3p GZMK granzyme K (granzyme 3; tryptase II) 
69 63 miR-301a-3p GZMK granzyme K (granzyme 3; tryptase II) 
70 62 miR-92b-3p AOAH acyloxyacyl hydrolase (neutrophil) 
72 62 miR-491-5p SFTPB surfactant protein B 
24 83 miR-185-5p CXCL9  chemokine (C-X-C motif) ligand 9 
10 94 miR-429 JUN jun proto-oncogene 
 
 
Figure 2: The confirmed 21 genes interacting with GNLY in IPA database 
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In this report, several databases and web tools 
analyses were approached to pinpoint pathways/ 
network and microRNAs targeting important 
proteins i.e. Granulysin contributing to 
pathogenesis of SJS/TEN. Predominantly, 
Granulysin were validated to be involved in SJS 
and TEN before. However, never were studied 
from microRNA perspective. Moreover, here we 
prove the potential microRNA regulators of 
Granulysin; miR-483-5p/miR-28-5p. 
 
REACTOME pathways [19] results for the 21 
gene clusters related to Granulysin indicated that 
the main pathways were associated with the 
following: 
 
1-Toll-like Receptor 1/2 TLR1:TLR2 Cascade 
2-Toll-like Receptor 2 (TLR2) Cascade 
3-Chemokine receptors bind chemokines 
4-Toll-Like Receptor 4 (TLR4) Cascade 
5-Toll-Like Receptors Cascades. 
 
DAVID tool [21] results were agreeing with the 
other pathways analyses; IPA. 
 
DAVID results for the 21 gene were as following: 
 
1- Chemokine signaling pathway  
2- inflammatory response i.e. SJS/TEN 
3- and Natural killer cell mediated cytotoxicity 
 
These data were generated through the use of 
Ingenuity Pathways Analysis, a web-delivered 
application that enables biologists to discover, 
visualize and explore therapeutically relevant 
networks significant to their experimental results, 
such as gene expression array data sets. For a 
detailed description of Ingenuity Pathways 
Analysis, visit www.Ingenuity.com. 
 
 
Figure 3: Genes targeted by the 18 miRs analyzed by IPA database 
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The complete genetics behind SCAR 
pathogenesis remains to be identified. STS and 
TEN, the major clinical manifestation of SCAR, 
continue to cause significant morbidity and 
mortality. In this report, databases and tools were 
used to investigate the differentially expressed 
microRNAs in SCAR. 
 
Obtained from miRDB were 79 miRNAs 
predicted to target the 21 genes that interact with 
the Granulysin gene, the core causal gene in 
SCAR. Then, by overlapping the over-expressed 
miRNAs and potential miRNAs that target the 21 
genes, a cluster of 18 miRNAs was obtained and 
found by Ingenuity pathway analysis (IPA) to be 
related to inflammation. Two significant DE 
miRNAs targeting Granylysin (miR-483-5p/miR-
28-5p) were found. MiR-GNLY loop interaction in 
hypersensitivity may be useful biomarkers for 
SCAR, including SJS and TEN. 
 
After the pathway-related microRNA clusters 
were identified, their genetic signature was 
generated to understand the pathogenesis of 
SJS and TEN. Our hypothesis that gene/miR 
signature can be applied to such a complex 
disease agrees with the genetic signature of 
HLA–B, –C, –A and –DRB1 alleles and 
cytochrome-P450 in a previous study [22]. Many 
significant pathways were also identified as 
hallmarks of SCAR, such as the necroptosis 
pathway that is mediated by annexin1 gene 
which ligates to FPR1 receptor [23]. Pathways 
are also important signatures for SCAR. In the 
current report, toll-like receptor was found to be 
the second most important in IPA and this 
pathway was proved to be involved in SJS and 
TEN [24]. There are many reports of other 
pathways in SCAR-related inflammatory 
response [25]. 
 
In terms of drugs causing SCAR, most 
candidates were, Allopurinol, Carbamazepine, 
furosemide Erythromycin and paracetamol [26]. 
While, in this study, specific Granulysin gene/miR 
cluster could potentially serve as a biomarker for 




Highlighted in this report are 18 Granulysin gene-
targeting microRNAs that can provide insight into 
the pathogenesis of SCAR. Specifically, 483-
5p/miR-28-5p, which are over-expressed in 
SCAR and validated to directly target the GNLY 
gene, are novel regulators of miRs that can 
modulate Granulysin gene expression. It is 
evident that the MiR-GNLY loop signature/control 
in hypersensitivity reactions can function as 
biomarkers for SCAR, including SJS and TEN. 
From the identified pathway-related microRNA 
clusters, a genetic signature is presented to 
understand the pathogenesis of SJS and TEN 
and will be highly valuable in the diagnosis and 
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